Saturday March 3, 2018
Burnaby General Hospital
3935 Kincaid St, Burnaby, BC V5G 2X6, Canada
Education Room A, 2nd Floor
It is our pleasure to have Dr. Philip Cohen introduce the topic of a new technology being introduced at Burnaby General Hospital to assist in the early diagnosis or treatment of Prostate Cancer. We look forward to seeing you there!
Division Head, Nuclear Medicine Lions Gate Hospital
STUDY TO EVALUATE 99MTC-MIP-1404 SPECT/CT IMAGING IN MEN WITH BIOPSY PROVEN LOW-GRADE PROSTATE CANCER (PROSPECT-AS)
PURPOSE OF STUDY 99mTc-MIP-1404 is a radioactive diagnostic imaging agent indicated for imaging men with newly diagnosed prostate cancer whose biopsy indicates a histopathologic Gleason grade of ≤ 3+4 severity and / or are candidates for active surveillance, but have planned to undergo radical prostatectomy. In these patients, the results may be used to help estimate the risk of a histopathologic Gleason grade of > 3+4. This Phase 3 study is designed to evaluate the specificity and sensitivity of 99mTc-MIP-1404 to detect clinically significant prostate cancer when compared to histopathology.